Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Astion Pharma (Three Products Worldwide Rights)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Portfolio of manufacturing rights for three dermatological drugs. The portfolio encompasses worldwide rights for Dermadexin, a topical treatment for seborrheic dermatitis; Pruridexin, a topical cream to treat chronic puritis; and ASF-1096, a treatment for discoid lupus erythematosus.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
Cipher Pharmaceuticals
Primary Office
  • Denmark

Astion Pharma (Three Products Worldwide Rights) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Astion Pharma (Three Products Worldwide Rights)‘s full profile, request access.

Request full access to PitchBook

Astion Pharma (Three Products Worldwide Rights) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Astion Pharma (Three Products Worldwide Rights)‘s full profile, request access.

Request full access to PitchBook